23andMe revolutionized genetic testing, building a database of over 15 million genotypes for research. However, the company now faces significant financial and legal challenges, casting doubt on its future. This article examines the scientific value of 23andMe's data, the potential implications of a go-private deal, and proposes an alternative solution: a strategic NIH acquisition to safeguard this invaluable resource and its impact on personalized medicine and data stewardship.
